Acadia Pharmaceuticals Inc. was downgraded after a drug setback, but strong sales and a robust pipeline offer investment ...

Jazz Pharmaceuticals' growth is anchored by Xywav and Epidiolex, both generating robust sales and supporting future oncology ...

Kingspan shares soared on Tuesday as the insulation manufacturer said it is considering floating its advanced building ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment ...

UEC Breakthrough Year Transitioning to Uranium Production in Wyoming, Burke Hollow Nearing Start-Up in Texas, and the Launch of U.S. Uranium Refining & Conversion Corp Creates ...

Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.

In the rapidly evolving landscape of healthcare, one company is boldly redefining the boundaries of medical communications. HCG, a global leader in the field, has recently reorganised seven smaller ...